Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Safety tips for the evolving pandemic. Plus: Which groups—such as those with cancer or HIV—are at higher risk for COVID-19 complications?
The monoclonal antibody combo is used as pre-exposure prophylaxis for immunocompromised people who may not respond to COVID-19 vaccines.
NCCN’s new recommendations for COVID-19 vaccines include children with cancer as well as their caregivers.
The update aims to help the public better protect themselves and understand their risk.
Extra vaccine doses, monoclonal antibodies and antivirals can help prevent severe illness.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.
Immunocompromised people ages 12 and older are also eligible for an additional shot.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
The CDC’s move triggered mixed feelings from the public and laid bare a split within the health care community.
Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.
Boosters reduced the risk of hospitalization and death by about 80% for people with HIV, cancer, autoimmune conditions or organ transplants.
Cancer patients undergoing treatment and those with suppressed immune systems eye the future—and the COVID pandemic’s wane—warily.
The largest peer-reviewed study of the Pfizer-BioNTech COVID vaccine in cancer patients finds no more, and no different, side effects.
Organ transplant recipients take immunosuppressive drugs that impair immune response to pathogens and vaccines.
People with moderate to severe immune suppression are eligible for a fourth COVID vaccine dose.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.